Close Menu

Personalis

The company is selling more than 3.9 million shares at $38 per share and has offered underwriters an option to add additional shares under the same terms.

The company brought in $20.2 million during the quarter, driven by strong biopharma revenue, with orders increasing for both its core services and new liquid biopsy offering.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.

Oppenheimer downgraded the company's shares to Perform from Outperform on Friday, based on valuation and expected headwinds from the pandemic.

The company priced about 6.6 million shares of its common stock at $19 per share, and is offering underwriters an option to purchase additional shares from a selling stockholder.

The company's Q2 revenue growth was driven by a 74 percent increase in revenues from the analytical services it provided to the VA MVP program.

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

Pages

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.